Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Patients With Hepatocellular Carcinoma (HCC)
NCT01003015Phase 2Completed
- Sponsor
- Bayer
- Start
- Sep 2009
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Started Sep 2009; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01003015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01003015.